「dopamine」の共起表現(1語右で並び替え)

「dopamine」の共起表現一覧(1語右で並び替え)

dopamine

1 2 次へ＞

1語右で並び替え

該当件数:362件

Two catecholamines, norepinephrine and dopamine, act as neuromodulators in the central nervou
ars to possess a general inhibitory action on dopamine activity in the brain, opposing the dopamine-
Dopamine activity enhancers such as BPAP and PPAP, whi
K-B receptors possess a complex regulation of dopamine activity in the brain.
has also been shown to significantly enhance dopamine activity in the mesolimbic pathway.
ry task, the greater the increase in abnormal dopamine activity in the striatum (green), thought to
Reduced dopamine activity due to receptor blockade
This results in a facilitation of dopamine activity, and for this reason, low dose amisu
benfluorex), dopamine agents (including dopamine uptake inhibitors
PD-168,077 is a drug which acts as a dopamine agonist selective for the D4 subtype, which i
Dihydroergocryptine is a dopamine agonist of the ergoline chemical class used a
g which acts as a potent, orally bioavailable dopamine agonist selective for the D4 subtype, which w
SKF-89,145 is a drug which acts as a dopamine agonist selective for the D1 subtype.
cts of pramipexole (and related D3-preferring dopamine agonist medications such as ropinirole) may i
Quinelorane is a drug which acts as a dopamine agonist selective for the D2 subtype.
odel, Cycloset), an ergoline derivative, is a dopamine agonist that is used in the treatment of pitu
Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antipark
CP-226,269 is a drug which acts as a dopamine agonist selective for the D4 subtype, which i
A dopamine agonist is a compound that activates dopamine
Ropinirole, a non-ergoline dopamine agonist
Ciladopa (AY-27,110) is a dopamine agonist with a similar chemical structure to
ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype.
s Requip, Ropark, Adartrel) is a non-ergoline dopamine agonist.
ith Parkinson's being treated with l-dopa - a dopamine agonist.
Terguride (INN) is a dopamine agonist.
Fencamfamine acts as an indirect dopamine agonist.
Dopamine agonists activate signaling pathways through
However, where dopamine agonists can mimic positive symptoms with sig
Dopamine agonists
een linked to the use of medications known as dopamine agonists, such as pramipexole .
dil seems to cause less drowsiness than other dopamine agonists.
nix Inc, which acts as a stimulant and potent dopamine and serotonin reuptake inhibitor.
, although one isomer blocks reuptake of only dopamine and noradrenaline, while the other blocks reu
It stimulates release of dopamine and acetylcholine in the brain in both rodent
ters, serotonine acting as an inhibitor while dopamine and norepinephrine act as a stimulator of sex
caused by largely increased amounts of serum dopamine and release of dopamine in place of norepinep
antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater
nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.
reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.
in the range >10,000 and so are selective for dopamine and noradrenaline reuptake, with little or no
neuropeptide Y release, as well as modulating dopamine and acetylcholine release.
nterleukine 1-beta (IL-1b) induced changes in dopamine and it's metabolites in the shell of the Nucl
on of the brain that produces and distributes dopamine and also brains “reward system”, or the neura
precursors mentioned above, namely tyrosine, dopamine and their derivatives.
t Columbia University that act as analogs for dopamine and other monoamines and enable an optical me
However, the link between dopamine and purine synthesis is a nucleotide called g
5-HT1A receptors in modulating the release of dopamine and serotonin in the brain, and their involve
nsmitters glutamate and aspartate, as well as dopamine and noradrenaline in the frontal cortex and h
understood, although inhibition of serotonin, dopamine and noradrenaline reuptake is thought to be i
sport several compounds, including serotonin, dopamine, and the neurotoxin 1-methyl-4-phenylpyridini
n brain states of intense meditators (reduced dopamine and increased oxytocin) that induce general r
6-OHDA enters the neurons via the dopamine and noradrenaline (aka norepinephrine) reupta
to the signaling in the conscious brain, like dopamine and serotonin (as mentioned above).
he Triptans but also interacts centrally with dopamine and adrenergic receptors.
eased Na+/K+ current and increased release of dopamine and glutamate.
reuptake of the neurotransmitters serotonin, dopamine and norepinephrine by interacting with the se
ynthesis of catecholamines, reduces levels of dopamine and cardiac norepinephrine, and inactivates t
rivate of spiperone that is used to study the dopamine and serotonin neurotransmitter system.
neurotransmitter (such as glutamate, GABA or dopamine) and one or more neuropeptides.
s a balanced reuptake inhibitor of serotonin, dopamine, and norepinephrine, and also has some weak r
ecoside and H2O, whereas its two products are dopamine and secologanin.
rivate of spiperone that is used to study the dopamine and serotonin neurotransmitter systems.
y potent inhibitor of the reuptake serotonin, dopamine, and norepinephrine.
duce a marked behavioural supersensitivity to dopamine and a marked rise in the number of dopamine D
f monoamines in the brain, such as serotonin, dopamine, and epinephrine.
hibitor, primarily inhibiting the reuptake of dopamine and noradrenaline.
B receptor is known to inhibit the release of dopamine and even appears to have neuroleptic effects
lass of compounds and increases the levels of dopamine and norepinephrine in the brain through reupt
touch can result in the release of oxytocin, dopamine, and serotonin, and in a reduction in stress
also contain, among other things, tyrosinase, dopamine and L-DOPA, and small amounts of amino acids,
urotransmitters as most, including serotonin, dopamine, and norepinephrine, are absorbed from the sy
n shown to inhibit the reuptake of serotonin, dopamine, and norepinephrine with IC50 values of 322 n
nes that respond to a neurotransmitter called dopamine, and is a potential therapeutic molecule asso
nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.
It also inhibits the reuptake of dopamine and serotonin, and acts as a mixed agonist-an
Lisuride is a dopamine and serotonin receptor partial agonist.
Other substituted phenethylamines, such as dopamine and epinephrine are neurotransmitters.
It also increases the release of dopamine and norepinephrine.
lar concentrations of both norepinephrine and dopamine and therefore an increase in adrenergic and d
has more pronounced serotonin antagonism than dopamine antagonism.
Azapride is the azide derivative of the dopamine antagonist clebopride.
s an analogue of spiperone, and also has some dopamine antagonist effects.
Bromopride (INN) is a dopamine antagonist with prokinetic properties widely
Nafadotride is a dopamine antagonist with reasonable selectivity for th
Azaperone acts primarily as a dopamine antagonist but also has some antihistaminic a
It is a potent dopamine antagonist with high affinity to the D2, D3,
(Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic eff
When a dopamine antagonist was injected into the reward regio
A dopamine antagonist is a drug which blocks dopamine re
Eticlopride is a dopamine antagonist used in pharmacological research.
lozapine, the first atypical antipsychotic, a dopamine antagonist.
uite similar to chlorpromazine, and acts as a dopamine antagonist.
It is an irreversible dopamine antagonist.
Dopamine antagonists such as antipsychotics and metocl
, or akathisia suffered as a result of taking dopamine antagonists, usually antipsychotic (neurolept
As with other dopamine antagonists, zuclopenthixol may sometimes ele
he unrestrained release of both serotonin and dopamine as with MDMA itself.
ia inducing the release of norepinephrine and dopamine as with its analogues pemoline and aminorex.
Shumaker founded Dopamine as a cassette only indie label in 1995 and me
This is credited to an increase in dopamine, because mania can be reduced by dopamine-blo
People with dopamine beta hydroxylase deficiency may have a parado
at (INN, codenamed SYN117) is an inhibitor of dopamine beta-hydroxylase, an enzyme that catalyzes th
Other names in common use include dopamine beta-hydroxylase, MDBH (membrane-associated d
maintains many of the structural features of dopamine beta-monooxygenase DBH.
In enzymology, a dopamine beta-monooxygenase (EC 1.14.17.1) is an enzym
xygenase (PHM; EC 1.14.17.3) is homologous to dopamine beta-monooxygenase (DBM; EC 1.14.17.1) this c
graphy (PET) scanning to assess the degree of dopamine binding to the D2 Dopamine receptor.
namely extrapyramidal symptoms as a result of dopamine blockade in subcortical areas of the brain.
ients) challenged the view that the amount of dopamine blocking was correlated with clinical benefit
onin function and may have slightly less of a dopamine blocking effect.
as a neurotransmitter with similar effects to dopamine), blue lotus extract (Nymphaea caerulea), nat
created when cocaine inhibits the reuptake of dopamine by DAT, which results in an increase in extra
I) is a drug which inhibits the metabolism of dopamine by the enzyme aromatic L-amino acid decarboxy
emical nerve in the brain) norepinephrine and dopamine by blocking the action of the norepinephrine
It releases dopamine by a similar mechanism to amphetamines, but i
Dopamine can then more readily bind neurons, which ove
more frequent administration, its effects on dopamine can become significant enough for binging and
ne transporter is responsible for most of the dopamine clearance in the prefrontal cortex, SNRIs wou
In Lophophora williamsii, dopamine converts into mescaline in a biosynthetic pat
evodopa, a precursor for the neurotransmitter dopamine, currently the drug-of-choice in treatment of
This article is about the dopamine D1 receptor agonist.
It is believed to work by blockading dopamine D1 and D2 receptors in the mesocortical and m
S-186,899) is a selective full agonist at the dopamine D1 and D5 receptors.
8.9), α2B (9.5), and α2C (8.9) receptors, the dopamine D1 (8.9), D2 (8.9), D3 (9.4), and D4 (9.0) re
s a potent and selective full agonist for the dopamine D1 receptor.
that acts as a selective full agonist at the dopamine D1 receptor.
For the dopamine D1 receptor agonist, see 6-Br-APB.
s also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline
adenosine A1/A2A heteromers and dopamine D1/D2 and D1/D3 heteromers) or between entire
pine derivative drug that acts as a selective dopamine D1/D5 receptor antagonist, with little affini
Memantine acts as an agonist at the dopamine D2 receptor.
Sulpiride is a selective antagonist at dopamine D2 and D3 receptors.
and researcher from UCLA, that correlated the Dopamine D2 Receptor Taq 1 allele with alcoholism.
Bromocriptine is a potent agonist at dopamine D2 receptors and various serotonin receptors.
a chemical once thought to be an irreversible dopamine D2 receptor antagonist; however, it was later
It has a high affinity for the dopamine D2, D3 and D4 receptors, as well as serotonin
Maximum expression of dopamine D3 receptors is noted in the islands of Calle
a potent and highly selective agonist for the dopamine D3 receptor.
ntagonist at both the 5HT2A receptor, and the Dopamine D4 receptor, but without blocking other dopam
cally: GTP deficiency) disorder, resulting in dopamine deficiency.
In the brain, COMT-dependent dopamine degradation is of particular importance in br
is the prescription of the minimum effective dopamine dose for individuals at risk.
results in lowered systematic catecholamine ( dopamine, epinephrine and norepinephrine) levels.
y glutamate, and also such as norepinephrine, dopamine, epinephrine, and serotonin, all of which fur
also involved in the production of serotonin, dopamine, epinephrine, and norepinephrine - neurotrans
the exocyclic position (mescaline, serotonin, dopamine, etc.) are usually attributed to amines rathe
lock the peripheral conversion of L-DOPA into dopamine for the purpose of reducing adverse side effe
timulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals of the
nd thus increase the release of serotonin and dopamine from nerve endings into the synaptic cleft.
armacological studies point to alterations in dopamine function and the endocannabinoid system.
phrenia cannot fully be explained in terms of dopamine function, but may also involve other neurotra
dental finding that a drug group which blocks dopamine function, known as the phenothiazines, could
smitters including serotonin, norepinephrine, dopamine, GABA, and glutamate.
(noradrenaline) and epinephrine (adrenaline), dopamine, gamma-aminobutyric acid (GABA), and glutamat
ls of DOPAC, a metabolic breakdown product of dopamine, have been shown to occur in striatal isolate
, the frontal lobes, and the neurotransmitter dopamine have also all been linked to schizophrenia.
ese animals L-Dopa, which is the precursor of dopamine, he could alleviate the symptoms.
An influential theory, known as the Dopamine hypothesis of schizophrenia, proposed that a
Like dopamine hypothesis, the development of the glutamate
The dopamine hypothesis.
compound has lent support to the inclusion of dopamine in the monoamine hypothesis of depression, D-
However, dopamine in most brain regions is cleared primarily by
e is a drug developed to mimic the actions of dopamine in the brain to help cope with restless legs
ons due to changes in the levels of hemolymph dopamine in its intermediate host, the crab Hemigrapsu
t of amphetamine (AMPH) use is an increase of dopamine in the synapse.
other drugs, cannabis increases the amount of dopamine in the synapses.
eveloped a method for measuring the amount of dopamine in brain tissues.
iated with low levels of the neurotransmitter dopamine in the brain.
Pergolide has some of the same effects as dopamine in the body.
It works by blocking the effects of dopamine in the brain, leading to diminished psychoses
In normal mice, levels of dopamine in the synapse rose to ten times normal level
ce the effectiveness of exogenously delivered dopamine, in the form of L-DOPA.
ar focus has been placed upon the function of dopamine in the mesolimbic pathway of the brain.
system via triggering a cascading release of dopamine in the brain.
Dopamine in the nucleus accumbens may have a role in e
affecting synthesis, storage, and release of dopamine into the synaptic cleft).
The third metabolic end-product of dopamine is norepinephrine (noradrenaline).
Dopamine is at the origin of DDS.
Dopamine is another example of a neurotransmitter.
receptor subtypes as it is the precursor for dopamine is rarily associated with these disorders.
Dopamine is a neurotransmitter associated with rewardi
laces spiperone binding in vitro and elevates dopamine levels in the striatum, indicating it acts as
It is able to increase dopamine levels in the nucleus accumbens.
Theanine also increases brain dopamine levels and has a low affinity for AMPA, kaina
He found that dopamine levels in the basal ganglia, a brain area imp
ect oxidative enzymes, and is associated with dopamine levels in the brain.
In DAT knockout mice, dopamine levels in the synapse (as measured by microdi
imals the drug reserpine caused a decrease in dopamine levels and a loss of movement control.
It increases serotonin, norepinephrine, and dopamine levels in the brain and is believed to act as
This combined effect only slightly elevates dopamine levels, giving vanoxerine only mild stimulant
Although SAMe is purported to increase dopamine levels, some research suggests it might actua
atum and prefrontal cortex, without affecting dopamine levels.
A steady influx of dopamine makes it difficult for addicts to shift their
at amphetamines, which trigger the release of dopamine, may exacerbate the psychotic symptoms in sch
drenergic receptor kinase-2 appears to affect dopamine metabolism.
lousy and persecution had different levels of dopamine metabolite HVA and Homovanillyl alcohol (whic
associated with schizophrenia, likely through dopamine modulation by nicotinic acetylcholine recepto
Three-dimensional model of the structure of a dopamine molecule.
antagonist, with no affinity for adrenaline, dopamine, muscarinic acetylcholine, or serotonin recep

1 2 次へ＞